The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.

Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...

More than 2,500 patients are currently waiting for that lifesaving transplant in Michigan. More than 100,000 are waiting ...

Dearring was diagnosed in 2010 with sarcoidosis — a chronic disease that caused debilitating lesions in her lungs. Her doctor’s news was shocking: She couldn’t leave the hospital until she ...

(RTTNews) - aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company, on Wednesday announced that it will present three important posters on efzofitimod at the American Thoracic Society or ...

The posters will cover the largest placebo-controlled trial in pulmonary sarcoidosis, real-world treatment patterns, and the incidence and mortality of the disease in the U.S. Efzofitimod ...

Stephanie Lee Griffin; Chief Operating Officer; Roivant Sciences Ltd. Matt Gline; Chief Executive Officer, Director; Roivant Sciences Ltd. Dave Risinger; Analyst; Le ...

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline ...

Q3 2024 Earnings Call Transcript February 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is $0.23, expectations were $-0.24. Operator: Ladies and gentlemen, thank you for ...

THE UK has been hit by a barrage of winter illnesses this year. Nasty winter bugs, including flu, COVID-19, RSV and norovirus ...